Divya Natesan, N/A (she/her/hers)

University of Pittsburgh, School of Medicine

Poster(s):

• PI-034 - ONCOLOGIST CONSIDERATIONS WHEN CHOOSING BETWEEN 200 MG EVERY-3-WEEK VERSUS 400 MG EVERY-6-WEEK DOSING OF PEMBROLIZUMAB MONOTHERAPY WITHIN UPMC HILLMAN CANCER CENTER NETWORK
  Wednesday, May 28, 2025

  5:00 PM - 6:30 PM East Coast USA Time